🇪🇺 Litfulo in European Union

EMA authorised Litfulo on 15 September 2023

Marketing authorisation

EMA — authorised 15 September 2023

  • Application: EMEA/H/C/006025
  • Marketing authorisation holder: Pfizer Europe MA EEIG
  • Local brand name: Litfulo
  • Indication: Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.
  • Status: approved

Read official source →

Litfulo in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is Litfulo approved in European Union?

Yes. EMA authorised it on 15 September 2023.

Who is the marketing authorisation holder for Litfulo in European Union?

Pfizer Europe MA EEIG holds the EU marketing authorisation.